Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Terminated × Prostatic Neoplasms × lanreotide × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 1 Pituitary Neoplasms 1 Neuroendocrine Tumors in Lung 1 Neuroendocrine Tumors 1 Gigantism 1 Gastrointestinal Neoplasms 1 Carcinoid Tumor 1 Acromegaly 1

Interventions

Docetaxel 48 Prednisone 27 Leuprolide 21 enzalutamide 19 bicalutamide 15 Magnetic Resonance Spectroscopy 14 Goserelin 12 Abiraterone Acetate 12 Radiotherapy 11 acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 10 abiraterone 9 cabazitaxel 8 Radiotherapy, Intensity-Modulated 8 olaparib 7 gallium 68 PSMA-11 7 Metformin 7 Ketoconazole 7 Gonadotropin-Releasing Hormone 7 Doxorubicin 7 Cyclophosphamide 7 Androgen Antagonists 7 luprolide acetate gel depot 6 Estramustine 6 pembrolizumab 5 cabozantinib 5 apalutamide 5 Radiosurgery 5 Mitoxantrone 5 Dexamethasone 5 Carboplatin 5

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01313273 2019-11-22

POSEIDON

Ipsen

Phase 3 Terminated

3 enrolled 4 charts

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡